Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-29
2008-12-16
Balasubram, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S231500, C514S256000, C514S269000, C544S317000, C544S320000, C544S336000, C544S050000, C544S111000
Reexamination Certificate
active
07465725
ABSTRACT:
This invention features pyrimidine compounds of formula (I):R1isaryl, or heteroaryl; each of R2and R4, independently, is Rc, halogen, nitro, cyano, isothionitro, SRc, or ORc; or R2and R4, taken together, is carbonyl; R3is Rc, alkenyl, alkynyl, ORc, OC(O)Rc, SO2Rc, S(O)Rc, S(O2)NRcRd, SRc, NRcRd, NRcCORd, NRcC(O)ORd, NRcC(O)NRcRd, NRcSO2Rd, CORc, C(O)ORc, or C(O)NRcRd; R5is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; X is O, S, S(O), S(O2), or NRc; Y is a covalent bond, CH2, C(O), C═N—Rc, C═N—ORc, C═N—SRc, O, S, S(O), S(O2), or NRc; Z is N or CH; one of U and V is N, and the other is CRc; and W is O, S, S(O), S(O2), NRc, or NC(O)Rc; in which each of Raand Rb, independently, is H, alkyl, aryl, heteroaryl; and each of Rcand Rd, independently, is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl.
REFERENCES:
patent: 6384032 (2002-05-01), Ono et al.
patent: 6660733 (2003-12-01), Sun et al.
patent: 6680315 (2004-01-01), Ono et al.
patent: 6693097 (2004-02-01), Ono et al.
patent: 6858606 (2005-02-01), Sun et al.
patent: 6958332 (2005-10-01), Sun et al.
patent: 7045517 (2006-05-01), Ono et al.
patent: 7067514 (2006-06-01), Ono et al.
patent: 2005/0250787 (2005-11-01), Sun et al.
patent: 2005/0282809 (2005-12-01), Ono et al.
patent: 2006/0030560 (2006-02-01), Sun et al.
patent: WO 00/62778 (2000-10-01), None
European Search Report dated Feb. 7, 2005.
International Search Report dated Jun. 12, 2003.
Trincheri, G., “Function and Clinical Use of Interleukin-12”, Current Opinion in Hematology, 4: 59-66, 1997.
Arvanitis et al., Non-Peptide Corticotropin-Releasing Hormone Antagonist: Syntheses and Structure-Activity Relationships of 2-Anilinopyrimidines and -triazines, J. Med. Chem., vol. 42, 1999, pp. 805-818.
Mylari, et al., Sorbitol Dehydrogenase Inhibitors (SDIs): A New Potent, Enantiometric SDI, 4-[2-1R-Hydroxy-ethyl)-pyrimidin-4yl]-piperazine-1-sulfonic Acid Dimethylamide, J. Med. Chem., vol. 44, 2001, pp. 2695-2700.
Nishigaki et al. “Synthesis of Iminodipyrimidnies”, Tetrahedron Letters. 7:539-542 (1969).
Becher, et al., “Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12”, The Journal of Clinical Investigation, 110(4), pp. 493-497 (2002).
Maeyama, et al., “Attenuation of bleomycln-induced pneumopathy in mice by monoclonal antibody to interleukin-12”, Am. J. Physiol. Lung Cell Mol. Physiol., 280 L1128-L1137 (2001).
Kostik Elena
Koya Keizo
Ono Mitsunori
Przewloka Teresa
Sun Lijun
Balasubram Venkataraman
Edwards Angell Palmer & & Dodge LLP
Hsi Jeffrey D.
Russett Mark D.
Synta Pharmaceuticals Corp.
LandOfFree
Pyrimidine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4048712